1282 / 1816
Gene expression profiles
Gene expression profiles: Mammaprint™ or Oncotype Dx Recurrence Score™
Patients with intermediate risk
•more accurately identifying patients who will gain the most benefit
•to gain additional prognostic and/or predictive information to complement
pathology assessment
•to predict response to adjuvant chemotherapy, in particular in patients with
ER-positive early breast cancer
The accurate integration of these new genomic tools into current clinical
practice and their added value is evaluated in two large prospective phase III
trials (MINDACT and TAILORx).
19-9-2017